Attention generic drug manufacturers! The FDA’s recent revision to its “ANDA Submissions—Amendments and Final Approval Requests” guidance throws open a clearer path to bringing your medications to market. This blog unpacks the crucial updates, empowering you to make informed decisions and accelerate approvals. What’s New? Timely Reviews: Clear timelines and recommendations guide amendment submissions for faster […]

Imagine Affordable access to life-saving biosimilars and generics, a medical landscape where cost doesn’t limit access to crucial therapies. But wait, the path leading there is a dizzying tightrope stretched across a chasm of regulatory complexity. Fear not, intrepid explorer! Let’s untangle the biosimilar and generics regulatory maze, ensuring your journey reaches triumphant fruition. Navigating

The development of new drugs involves a rigorous journey, with regulations guiding each step. One crucial aspect is charging for investigational drugs under an Investigational New Drug (IND) application. This topic has generated significant discussion and inquiries. To address these complexities, the Food and Drug Administration (FDA) offers comprehensive guidance through “Questions and Answers for

For decades, the life sciences industry has relied on mountains of paper to navigate the complex world of regulatory submissions. From clinical trial data to manufacturing specifications, these filing cabinets held the key to bringing new drugs, devices, and therapies to market. But the tide is turning. The cumbersome paper-based approach is giving way to